Literature DB >> 6144477

Effect of route of administration and biliary excretion on the pharmacokinetics of isotretinoin in the dog.

S Cotler, S Chen, T Macasieb, W A Colburn.   

Abstract

Oral, intraportal, iv doses of isotretinoin were administered to dogs before and after bile duct cannulation to determine the effect of route of administration and biliary excretion on the pharmacokinetics of this compound. Blood and bile samples were collected and analyzed for isotretinoin using a gradient elution high performance liquid chromatographic method. Blood concentrations were decreased after bile duct cannulation. Decreases in the area under the blood concentration-time curves were greatest following oral dosing, intermediate following intraportal dosing, and least following iv dosing. These results indicate that biliary excretion impacts on the blood profile of isotretinoin as a function of route of administration and that the differences are the result of differences in first pass clearance. In addition, the apparent bioavailability of isotretinoin was 14% in bile cannulated dogs and 54% in the intact (uncannulated) animals, suggesting that enterohepatic recycling of isotretinoin may contribute to its oral bioavailability. Isotretinoin was excreted in the bile; predominantly as a conjugate. The largest percentage (approximately 27%) of the dose was excreted in the bile following intraportal infusion, an intermediate percentage (approximately 8.5%) after iv dosing, and the smallest percentage (approximately 3.3%) after oral dosing. When the amount of drug excreted in bile as intact drug and conjugate is divided by the area under the systemic blood concentration--time curve, the resulting apparent biliary clearances following oral and intraportal administration were almost identical whereas the apparent biliary clearance after iv dosing was substantially less.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144477

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  A phase 1 and pharmacokinetic study using the aromatic retinoic acid analogue dichloroetretinate (Ro 12-7554).

Authors:  B A Zonnenberg; A von Dijk; C P Vendrik; J H Schornagel; A Struyvenberg
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  The pharmacokinetics of alpha-methyldopa in dogs.

Authors:  G M Kochak; W D Mason
Journal:  J Pharmacokinet Biopharm       Date:  1985-08

3.  Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice.

Authors:  V I Avramis; K K Chan; M M Solorzano; Z L Chen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics of the retinoids.

Authors:  R W Lucek; W A Colburn
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.